May 14th 2024
Dynavax is currently reviewing FDA feedback and strategizing a meeting to discuss their HEPLISAV-B 4-dose regimen for hemodialysis patients, determining the path forward toward approval.
CDC Publishes 2 Reports on Hepatitis Incidence Rates and Progress Towards 2025 Goals
September 10th 2023The federal agency’s reports shows decreases in both hepatitis A and B, but hepatitis C saw a significant increase during 2021. However, the investigators note the pandemic may have impacted statistics and progress towards goals.
Read More
WHO Updates Recommendations for HIV, Hepatitis, STI Interventions in Prisons
July 26th 2023The update refreshes the organization's 2022 guidance on HIV, viral hepatitis, and STI prevention, diagnosis, treatment, and care for key populations, focusing on people in prisons and other closed settings.
Read More